LQDA

Liquidia Corp

Agios wins EU approval for Pyrukynd in adult thalassemia patients, expanding the drug's reach as the only authorized therapy for a broad patient population.

Gilead wins FDA approval for Hepcludex, the first U.S. therapy for chronic HDV, while Trodelvy advances in Europe for TNBC.

NVO's Wegovy pill gets CHMP backing, moving it closer to becoming the first oral GLP-1 treatment approved in the EU for weight management.

Black Diamond Therapeutics shares sink as phase II silevertinib data show NSCLC efficacy and CNS activity, but raise investor concerns on the early nature of the dataset.

ALT advances pemvidutide in MASH, AUD and ALD, with phase III plans and promising liver disease data fueling investor focus.

Teva aims to expand its schizophrenia portfolio after the EMA accepts its filing for olanzapine long-acting injectable (TEV-'749).

DYN shares jump 10% after launching a phase III study of z-rostudirsen in Duchenne muscular dystrophy patients amenable to exon 51 skipping.

STOK rides high as zorevunersen advances in late-stage Dravet syndrome studies and heads toward FDA filing plans.

LQDA, XOM, VLO and FANG were highlighted as low-beta stocks as Middle East tensions fuel market volatility.